AMR Focus Nosopharm specializes in researching and developing novel anti-infectives to combat antimicrobial resistance, presenting opportunities to partner on early-stage drug discovery, platform licensing, or co-development arrangements with pharmaceutical companies seeking new AMR solutions.

Lead Program The lead candidate NOSO-502 and related Odilorhabdin programs offer a concrete near-term collaboration target for in-licensing, joint development, or research service partnerships with firms aiming to bolster their infectious disease pipelines.

Strategic Partnerships Historical collaboration with Evotec and ongoing relationships suggest openness to third-party partnerships, enabling BD teams to propose contract research, capability access, or strategic equity collaborations to accelerate clinical progression.

Financing Signals Recent financing rounds indicate investor confidence and potential readiness for collaboration that leverages external funding, making co-development or milestone-based deals attractive for sponsors seeking de-risked entry points.

Geographic Focus Headquartered in Lyon with a European funding footprint, Nosopharm may be a fit for regional partnerships, out-licensing discussions, or grant-backed programs within Europe, tapping into EU research networks and AMR funding streams.